October 2021, Volume 7, Issue 12

October 2021

Volume 7, Issue 12

This issue tells the long story of drug shortages, demystifies transfusion services, and more.

Table of Contents

October 2021 Issue

APs Take the Lead in Achieving Programmatic Goals: Part One

Friday, October 1st, 2021
Advanced practitioners (APs) are uniquely positioned within their practices to implement change, and make sure that the changes stick. ASH Clinical News’ Associate Editor...
You Make the Call

Reader Responses: How would you treat this transplant-ineligible patient with Ph+ ALL?

Friday, October 1st, 2021
Here’s how readers responded to a You Make the Call question about treatment options for a transplant-ineligible patient with Philadelphia chromosome-positive (Ph+) acute lymphocytic...

Editor’s Corner: Check Your Bia-Cis at the Door

Friday, October 1st, 2021
I know I’m a proud parent, but my teenaged sons’ respect for and acceptance of their friends’ preferred pronouns, dress, and names, as well...

October 2021 Issue

The Society Pages

NCI Grants $1.8M for Cancer Genome Atlas Research, Sarah Cannon Names Navneet Majhail Physician-in-Chief...

Friday, October 1st, 2021
Sarah Cannon Appoints Navneet Majhail as Deputy Physician-in-Chief of Blood Cancers Sarah Cannon Research Institute has named Navneet Majhail, MD, deputy physician-in-chief of blood cancers...
ASH Directions

Key Dates and Safety Measures for the 2021 ASH Annual Meeting, and more

Friday, October 1st, 2021
Key Dates and Safety Measures for the 2021 ASH Annual Meeting The 63rd American Society of Hematology (ASH) Annual Meeting and Exposition will take place...

Rituximab Biosimilars Versus Originator: Comparing Long-Term Survival Benefit in DLBCL

Friday, October 1st, 2021
A study published in Blood Advances found the three-year rate of overall survival (OS) was similar between Dutch patients with diffuse large B-cell lymphoma...
WIB_icon

Does MRD Predict PFS in Patients With CLL on Indefinite Ibrutinib-Based Therapy?

Friday, October 1st, 2021
According to research published in Blood, measurable residual disease (MRD) was not associated with improved progression-free survival (PFS) in patients with chronic lymphocytic leukemia...
WIB_icon

Defining Incidence and Mortality Rates of Intracranial Hemorrhage in Patients With Hemophilia

Friday, October 1st, 2021
Compared with the general population, intracranial hemorrhage (ICH) rates are higher in all patients with hemophilia, according to a study published in Blood. Reported...

Therapeutic Anticoagulation Does Not Prevent PVT Recurrence After Liver Transplant

Friday, October 1st, 2021
In patients with cirrhosis who have portal vein thrombosis (PVT) and undergo liver transplantation, therapeutic anticoagulation was associated with significantly higher rates of bleeding...

Study Explores Molecular Landscape, Prognostic Impact of FLT3-ITD Insertion Site in Patients With AML

Friday, October 1st, 2021
In an analysis of the phase III RATIFY trial published in Leukemia, researchers examined the molecular landscape of FLT3 internal tandem duplication (ITD) mutations...

Is Dose-Dense BV-ICE an Effective Salvage Option in Relapsed/Refractory Classical Hodgkin Lymphoma?

Friday, October 1st, 2021
For patients with relapsed/refractory classical Hodgkin lymphoma (cHL), second-line therapy with a combination of intensive dose-dense brentuximab vedotin (BV) and ifosfamide, carboplatin, and etoposide...

Evaluating Venetoclax Plus Daratumumab and Dexamethasone in Relapsed/Refractory MM

Friday, October 1st, 2021
Treatment with oral BCL-2 inhibitor venetoclax induced deep and durable responses in patients with relapsed or refractory multiple myeloma (MM), especially those with t(11;14)...

Patient-Reported Outcome Questionnaire Shows Promise for Monitoring ITP

Friday, October 1st, 2021
A draft version of a 10-item patient-reported outcome (PRO) questionnaire has been developed to evaluate the impact of immune thrombocytopenia (ITP) on patients and...

Nearly Half of Transgender Patients Report Discrimination

Friday, October 1st, 2021
A recent report by the Center for American Progress (CAP) found that nearly 50% of transgender people in the U.S. have experienced mistreatment by...

New U.S. Department of Health and Human Services Office Will Address Climate Change as...

Friday, October 1st, 2021
The U.S. Department of Health and Human Services (HHS) has launched the new Office of Climate Change and Health Equity to address the public...
WIB_icon

Asciminib Superior to Bosutinib in Chronic-Phase CML

Friday, October 1st, 2021
Asciminib was more effective than bosutinib at improving the rate of a major molecular response in patients with chronic myeloid leukemia in chronic phase...

New Plan to Cover Uninsured in Non-Medicaid Expansion States

Friday, October 1st, 2021
As part of a $3.5 trillion package proposal, Congressional Democrats are crafting a new federal program to provide health insurance coverage to more than...

Cognitive Decline Observed Six Months After Chemotherapy in Patients With Lymphoma

Friday, October 1st, 2021
Patients with lymphoma tend to report and show signs of worsening cognitive function at six months after chemotherapy compared with healthy controls, according to...

Zanubrutinib Approved for Waldenström Macroglobulinemia

Friday, October 1st, 2021
The U.S. Food and Drug Administration (FDA) has approved zanubrutinib for the treatment of adult patients with Waldenström Macroglobulinemia (WM). This approval is based on...

Gavo-Cel Granted Orphan Drug Designation for Cholangiocarcinoma

Friday, October 1st, 2021
The FDA has granted orphan drug designation to T-cell therapy gavocabtagene autoleucel (gavo-cel) for the treatment of cholangiocarcinoma. TCR2 Therapeutics, the manufacturer of gavo-cel, is...

October 2021 Issue

Pulling Back the Curtain: Angela C. Weyand, MD

Friday, October 1st, 2021
In this edition, Angela C. Weyand, MD, talks about harnessing the power of social media to network with colleagues, educate the public about hematology,...

The Drug Shortages Dilemma

Friday, October 1st, 2021
In hematology/oncology, drug shortages typically affect older, less expensive drugs, but when no alternatives are available, clinicians may struggle to provide the best care. It’s...

Blood and Bugs: An Interview With Nancy Berliner, MD, and May Berenbaum, PhD

Friday, October 1st, 2021
In 1971, Nancy Berliner, MD, and May Berenbaum, PhD, met as roommates during their freshman year at Yale University. Fifty years later, they are...

October 2021 Issue

What Happens in the Blood Bank?

Friday, October 1st, 2021
Partnership between transfusion services and hematology is vital to the specialty Transfusion medicine is an essential part of hematology practice, with blood transfusion playing an...
You Make the Call

You Make the Call: How would you treat this transplant-ineligible patient with Ph+ ALL?

Friday, October 1st, 2021
This month, Geoffrey Uy, MD, discusses treatment options for a transplant-ineligible patient with Philadelphia chromosome-positive (Ph+) acute lymphocytic leukemia (ALL). And don't forget to check...